DISCOVER is a Marie Sklodowska-Curie and Horizon 2020 project bringing together researchers in the fields of cell death signalling, immunology, protein structural chemistry, drug design, bioinformatics and computational biology in a network that will exchange reagents, technologies and knowledge.
This cross-sectoral network will form a synergistic environment that aims to aid in understanding how the death ligand-death receptor signalling network shapes tumour – immune editing processes. The research programme will lead to better understanding of the evolving role of non-canonical cell death signalling in driving tumour cell motility and invasion and inhibition of tumour immune surveillance.


Our knowledge is very limited about the impact of death ligand-death receptor signalling on tumour- immune communication, but there is a strong rationale that death ligands sculpt the immune components of the tumour tissue driving immune escape and tumour progression.
The DISCOVER programme aims to address the role of the death ligand-death receptor signalling system across the three phases of tumour immune editing (elimination, equilibrium and escape). This aim is addressed under three specific objectives:
1. Identify approaches to block death receptor-induced tumour cell motility/invasion.
2. Determine strategies to block death ligand-induced tumour immune tolerance.
3. Identify mechanisms to activate intracellular DR-mediated death signalling.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 777995.